AngioDynamics Granted Patent for Laser Treatment Innovation
AngioDynamics Granted Patent for Laser Treatment Innovation
QUEENSBURY, N.Y., Oct 04, 2007 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the Company Patent No. 7,273,478, entitled "Endovascular Treatment Device Having a Fiber Tip Spacer." This patent covers an endovascular laser treatment device with a spacer that positions the fiber tip away from the vessel wall, and for the method of using that device.
AngioDynamics has additional related patent applications pending before the USPTO covering venous treatment devices and methods using advanced non-contact technology designed to further enhance treatment outcomes after laser surgery.
"This patent is an important addition to our growing intellectual property portfolio covering the treatment of venous disease using non-contact devices to minimize patient discomfort and bruising," commented Eamonn Hobbs, AngioDynamics President and CEO. "Innovation is a hallmark of AngioDynamics, and as a recognized leader in the treatment of venous disease we are always looking to enhance our product portfolio, especially when it comes to improving the patient's experience. We are continuing to develop this portfolio and look forward to further, solid intellectual property in this area."
About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.
About Forward-Looking Statements
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 2, 2007, may affect the actual results achieved by the Company.
SOURCE: AngioDynamics, Inc.
AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or
EVC Group, Inc.
Jennifer Beugelmans, 646-201-5447 (Investor Relations)
jbeugelmans@evcgroup.com
Doug Sherk, 646-201-5447 (Investor Relations)
dsherk@evcgroup.com
Steve DiMattia, 646-201-5445 (Media)
sdimattia@evcgroup.com